ALTSTATION.IO

CME Group Inc. (CME) Stock Analysis

By Nova Skye | AltStation.io | Updated November 03, 2026

Price

$305.06

Change

+0.63%

Market Cap

$109.19B

Avg Volume

1.9M

Company Overview

Headquartered in Chicago, Illinois, CME Group operates in the Financial Services sector within the Financial Data and Stock Exchanges industry. The company runs the premier global marketplace for trading futures and options across interest rates, equity indexes, foreign exchange, energy, metals, and agricultural commodities. It sells trade execution, market data feeds, and clearing services to institutional investors, corporations, central banks, and professional traders. Clearing and transaction fees drive the engine of the business, historically generating roughly 81% of total revenues.

CME Group is the dominant market leader in global derivatives trading, not a challenger fighting for market relevance. Its biggest competitive moat is CME Clearing, which acts as the central counterparty for trades and delivered over $95 billion in daily margin efficiencies to clients in Q2 2026. While competitors like Intercontinental Exchange and Cboe Global Markets vie for volume across select asset classes, CME’s deep liquidity pool creates massive switching costs that keep traders locked in.

The business is steadily expanding its cash-generative footprint, with clearing and transaction fees pulling in $1.4 billion in Q2 2026 following $5.28 billion in 2025. Tracing its roots back to 1898 and adopting the CME Group name in July 2007, management continues to diversify its product lineup through micro-sized contracts and sports index futures with FutureSports. CME operates as a high-margin toll road for financial markets, monetizing surging hedging volume without taking on balance sheet trading risk.

Key Financials

Market Cap

$109.19B

Revenue

$6.96B

EBITDA

$4.94B

Gross Margin

100.0%

Profit Margin

63.5%

Revenue Growth

13.0%

Total Cash

$2.33B

Total Debt

$3.85B

Free Cash Flow

$3.05B

52-Week Price Performance Analysis

Price Statistics

P/E Ratio

25.00

Forward P/E

23.06

Beta

0.18

52-Week High

$329.16

52-Week Low

$218.31

EPS

$12.20

50-Day Avg

$280.33

200-Day Avg

$280.19

Price/Book

4.11

Technical Analysis

CME trades at $305.06, placing it 88% of the way from its $217.29 52-week low to its $318.32 high. The stock is 3.80% below that high and 40.94% above the low, so the broader trend remains strong. Price is 5.25% above the 20-day moving average of $290.97, backed by 13.41% momentum over the last 20 trading days. Five-day momentum has slipped to -0.59%, showing that the rally has recently lost some speed. Near-term support is $261.98, while $308.06 is the immediate resistance level.

Recent News and Developments

CME launches MLB futures for all 30 teams

CME Group made MLB futures available for all 30 teams on November 2. The contracts trade on CME Globex and can be submitted for clearing through CME ClearPort. Source: CME Group

CME shares rebound to $306.24

CME fell 4.73% to $293.48 on October 27, then recovered to $306.24 by November 2. The stock gained 2.27% on October 30 and another 1.02% on November 2, recouping most of the initial selloff. Source: StockAnalysis.com

Brazilian real futures volume hits record

CME’s Brazilian real futures traded a record 498,498 contracts on October 26, representing about $9.2 billion in notional value. Volume was 11 times the year-to-date daily average and more than doubled the previous record of 191,325 contracts. Source: StreetInsider

Market Sentiment and Analyst Recommendations

Bull Case

CME has $6.96 billion in revenue and 13.0% revenue growth, giving investors real expansion rather than a purely defensive story. The analyst consensus is buy across 16 analysts, with a $317.06 target compared with the current $305.06 price. The bullish target reaches $367.00, although the analyst range is unusually wide. Trading activity is producing clear catalysts: Brazilian real futures hit a record 498,498 contracts on October 26, representing about $9.2 billion in notional value. That volume was 11 times the year-to-date daily average and more than double the previous record of 191,325 contracts. CME also launched MLB futures for all 30 teams on November 2, expanding the products available through CME Globex and CME ClearPort. The buy case is straightforward: double-digit revenue growth, strong price momentum, and new or heavily traded contracts can support further upside.

Bear Case

CME is not cheap at 25.00 times earnings, especially with the stock already 88% of the way through its 52-week range. The current price is just 3.80% below the $318.32 high, leaving less room for disappointment. CME has $3.85 billion in total debt against $2.33 billion in total cash, so debt exceeds available cash. The stock also fell 4.73% to $293.48 on October 27, showing that investors can quickly reprice it even during a strong broader trend. Chief Information Officer Sunil Cutinho sold 5,000 shares at $298.70 that day for $1,493,500, with 20,037 shares remaining, and the filing did not identify the sale as part of a Rule 10b5-1 plan. The analyst range of $227.00 to $367.00 shows major disagreement about fair value. At $305.06, the biggest risk is paying a full valuation just as five-day momentum has turned negative at -0.59%.

What to Watch

The first test is whether CME can break above the near-term resistance level of $308.06. A move toward the $318.32 52-week high would keep the 20-day momentum trend of 13.41% intact, while a fall below the $290.97 moving average would weaken it. The $261.98 30-day low is the key near-term support threshold if selling accelerates. Investors should track whether the 13.0% revenue growth rate holds and whether revenue continues above the current $6.96 billion level. Watch whether Brazilian real futures activity remains strong after the record 498,498-contract session on October 26. The November 2 MLB futures launch also needs to show that adding contracts for all 30 teams can generate meaningful trading activity. Finally, compare the stock with the $317.06 analyst target because the current $305.06 price has already closed much of that gap.

Analyst Consensus

BUY

Based on 16 analyst opinions

Low Target

$227.00

Mean Target

$317.06

High Target

$367.00

Earnings and Financial Data

Sector

Financial Services

Industry

Financial Data & Stock Exchanges

Employees

3,875

Earnings & Dividends

Next Earnings

Oct 21, 2026

EPS (Trailing)

$12.20

Dividend Yield

172.0%

Payout Ratio

92.6%

Frequently Asked Questions

Is CME a good stock to buy?

The recommendation is buy based on 16 analysts, and revenue growth is 13.0%. The takeaway is that the data supports a bullish view, but the stock is already near the top of its 52-week range.

What is CME’s price target?

The analyst target is $317.06, with estimates ranging from $227.00 to $367.00. The takeaway is that analysts see some upside from $305.06, but their forecasts vary widely.

What is CME’s 52-week high and low?

The technical price series shows a 52-week high of $318.32 and a low of $217.29. The takeaway is that CME sits near the high at 88% of the way through that range.

Is CME stock overvalued?

CME trades at a P/E ratio of 25.00 and has a market capitalization of $109.19 billion. The takeaway is that investors are paying a substantial earnings multiple for 13.0% revenue growth.

What are CME’s support and resistance levels?

Near-term support is the 30-day low of $261.98, while near-term resistance is the 30-day high of $308.06. The takeaway is that $308.06 is the immediate level CME must clear to extend its advance.

Related Stock Reports

Disclaimer: This report is for informational purposes only and does not constitute financial advice. The analysis and opinions expressed are those of AltStation.io and should not be relied upon as the sole basis for investment decisions. Always conduct your own research and consult with a qualified financial advisor before making investment decisions. Past performance does not guarantee future results. Updated November 03, 2026.